SGLT2i-associated ketoacidosis patients receive significantly lower insulin doses vs those with T1D ketoacidosis: JAMA
Australia: A new retrospective cohort study revealed a clinically relevant reduction in the doses of insulin administered over the first 24 hours of treatment in patients with SGLT2 inhibitor-associated diabetic ketoacidosis (DKA) compared with patients with type 1 diabetes DKA. There seems no clarity on whether the protracted duration of SGLT2 inhibitor DKA is a […]